Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study

Jaume Galceran, Zoé Uhry, Rafael Marcos-Gragera, Joan Borràs, GRELL EUROCARE-5 Working Group, Roberta De Angelis, Massimiliano Caldora, Eugenio Carrani, Silvia Giovanna Luisa Francisci, Sandra Mallone, Daniela Pierannunzio, Paolo Roazzi, Silvia Rossi, Mariano Santaquilani, andrea tavilla

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In Europe as a whole, survival from skin malignant melanoma (SMM) has increased constantly since the 1980s. The aim of the SUDCAN collaborative study was to compare the trends in the 5-year net survival from SMM and in related excess mortality rate between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland). The data were extracted from the EUROCARE-5 database (end of follow-up: 01 January 2009). First, the net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 in Belgium and Portugal. The analyses were carried out using a flexible excess rate modeling. Over the 2000-2004 period, the 5-year net survival from SMM ranged from 79 (Portugal) to 90% (Switzerland). In all countries, net survival was higher in women versus men and in young versus old age groups. From 1992 to 2004, the 5-year net survival increased the most in the countries with the lowest survivals in 1992 (+9% in Italy and Spain vs. +2% in Switzerland or +4% in France). The differences between countries decreased between 1992 and 2004. Although survival increased to a lower or higher extent in all countries during the period studied, significant differences in net survival from SMM persisted among the six countries studied. Health policies should mainly enhance early diagnosis by increasing public awareness and with screening campaigns. Furthermore, new immunotherapies, which will be approved soon hopefully, should also be used to improve the outcomes of SMM treatment.
Original languageEnglish
Pages (from-to)S77-S84
JournalEuropean Journal of Cancer Prevention
Volume26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Melanoma
Skin
Survival
Population
Switzerland
Portugal
Spain
Italy
France
Belgium
Mortality
Health Policy
Immunotherapy
Early Diagnosis
Age Groups
Demography
Databases

Keywords

  • Journal Article

Cite this

Galceran, J., Uhry, Z., Marcos-Gragera, R., Borràs, J., Group, GRELL. EUROCARE. W., De Angelis, R., ... tavilla, A. (2017). Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study, S77-S84. https://doi.org/10.1097/CEJ.0000000000000306

Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study. / Galceran, Jaume; Uhry, Zoé; Marcos-Gragera, Rafael; Borràs, Joan; Group, GRELL EUROCARE-5 Working; De Angelis, Roberta; Caldora, Massimiliano; Carrani, Eugenio; Francisci, Silvia Giovanna Luisa; Mallone, Sandra; Pierannunzio, Daniela; Roazzi, Paolo; Rossi, Silvia; Santaquilani, Mariano; tavilla, andrea.

In: European Journal of Cancer Prevention, Vol. 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study, 01.01.2017, p. S77-S84.

Research output: Contribution to journalArticle

Galceran J, Uhry Z, Marcos-Gragera R, Borràs J, Group GRELLEUROCAREW, De Angelis R et al. Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention. 2017 Jan 1;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S77-S84. https://doi.org/10.1097/CEJ.0000000000000306
Galceran, Jaume ; Uhry, Zoé ; Marcos-Gragera, Rafael ; Borràs, Joan ; Group, GRELL EUROCARE-5 Working ; De Angelis, Roberta ; Caldora, Massimiliano ; Carrani, Eugenio ; Francisci, Silvia Giovanna Luisa ; Mallone, Sandra ; Pierannunzio, Daniela ; Roazzi, Paolo ; Rossi, Silvia ; Santaquilani, Mariano ; tavilla, andrea. / Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study. In: European Journal of Cancer Prevention. 2017 ; Vol. 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study. pp. S77-S84.
@article{1d9188a4db7b4bd78b5e4d71e93fbe35,
title = "Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study",
abstract = "In Europe as a whole, survival from skin malignant melanoma (SMM) has increased constantly since the 1980s. The aim of the SUDCAN collaborative study was to compare the trends in the 5-year net survival from SMM and in related excess mortality rate between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland). The data were extracted from the EUROCARE-5 database (end of follow-up: 01 January 2009). First, the net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 in Belgium and Portugal. The analyses were carried out using a flexible excess rate modeling. Over the 2000-2004 period, the 5-year net survival from SMM ranged from 79 (Portugal) to 90{\%} (Switzerland). In all countries, net survival was higher in women versus men and in young versus old age groups. From 1992 to 2004, the 5-year net survival increased the most in the countries with the lowest survivals in 1992 (+9{\%} in Italy and Spain vs. +2{\%} in Switzerland or +4{\%} in France). The differences between countries decreased between 1992 and 2004. Although survival increased to a lower or higher extent in all countries during the period studied, significant differences in net survival from SMM persisted among the six countries studied. Health policies should mainly enhance early diagnosis by increasing public awareness and with screening campaigns. Furthermore, new immunotherapies, which will be approved soon hopefully, should also be used to improve the outcomes of SMM treatment.",
keywords = "Journal Article",
author = "Jaume Galceran and Zo{\'e} Uhry and Rafael Marcos-Gragera and Joan Borr{\`a}s and Group, {GRELL EUROCARE-5 Working} and {De Angelis}, Roberta and Massimiliano Caldora and Eugenio Carrani and Francisci, {Silvia Giovanna Luisa} and Sandra Mallone and Daniela Pierannunzio and Paolo Roazzi and Silvia Rossi and Mariano Santaquilani and andrea tavilla",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/CEJ.0000000000000306",
language = "English",
volume = "26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study",
pages = "S77--S84",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study

AU - Galceran, Jaume

AU - Uhry, Zoé

AU - Marcos-Gragera, Rafael

AU - Borràs, Joan

AU - Group, GRELL EUROCARE-5 Working

AU - De Angelis, Roberta

AU - Caldora, Massimiliano

AU - Carrani, Eugenio

AU - Francisci, Silvia Giovanna Luisa

AU - Mallone, Sandra

AU - Pierannunzio, Daniela

AU - Roazzi, Paolo

AU - Rossi, Silvia

AU - Santaquilani, Mariano

AU - tavilla, andrea

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In Europe as a whole, survival from skin malignant melanoma (SMM) has increased constantly since the 1980s. The aim of the SUDCAN collaborative study was to compare the trends in the 5-year net survival from SMM and in related excess mortality rate between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland). The data were extracted from the EUROCARE-5 database (end of follow-up: 01 January 2009). First, the net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 in Belgium and Portugal. The analyses were carried out using a flexible excess rate modeling. Over the 2000-2004 period, the 5-year net survival from SMM ranged from 79 (Portugal) to 90% (Switzerland). In all countries, net survival was higher in women versus men and in young versus old age groups. From 1992 to 2004, the 5-year net survival increased the most in the countries with the lowest survivals in 1992 (+9% in Italy and Spain vs. +2% in Switzerland or +4% in France). The differences between countries decreased between 1992 and 2004. Although survival increased to a lower or higher extent in all countries during the period studied, significant differences in net survival from SMM persisted among the six countries studied. Health policies should mainly enhance early diagnosis by increasing public awareness and with screening campaigns. Furthermore, new immunotherapies, which will be approved soon hopefully, should also be used to improve the outcomes of SMM treatment.

AB - In Europe as a whole, survival from skin malignant melanoma (SMM) has increased constantly since the 1980s. The aim of the SUDCAN collaborative study was to compare the trends in the 5-year net survival from SMM and in related excess mortality rate between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland). The data were extracted from the EUROCARE-5 database (end of follow-up: 01 January 2009). First, the net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 in Belgium and Portugal. The analyses were carried out using a flexible excess rate modeling. Over the 2000-2004 period, the 5-year net survival from SMM ranged from 79 (Portugal) to 90% (Switzerland). In all countries, net survival was higher in women versus men and in young versus old age groups. From 1992 to 2004, the 5-year net survival increased the most in the countries with the lowest survivals in 1992 (+9% in Italy and Spain vs. +2% in Switzerland or +4% in France). The differences between countries decreased between 1992 and 2004. Although survival increased to a lower or higher extent in all countries during the period studied, significant differences in net survival from SMM persisted among the six countries studied. Health policies should mainly enhance early diagnosis by increasing public awareness and with screening campaigns. Furthermore, new immunotherapies, which will be approved soon hopefully, should also be used to improve the outcomes of SMM treatment.

KW - Journal Article

U2 - 10.1097/CEJ.0000000000000306

DO - 10.1097/CEJ.0000000000000306

M3 - Article

VL - 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study

SP - S77-S84

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

ER -